Vanda's VQW — 765 misses primary endpoint in Phase III social anxiety trial

Vanda Pharmaceuticals put its VQW-765 program on hold pending further analysis following disappointing Phase III results. Results announced today showed the 546-adult social anxiety disorder trial missed its primary and key secondary endpoints. The findings did not confirm earlier Phase II results supporting the drug’s potential to treat acute anxiety. VQW-765 was safe and well tolerated, consistent with prior studies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref. ID: 202610141700PR_NEWS_USPR_____PH71973) on October 14, 2026, and is solely responsible for the information contained therein. (C)